2020-10-29| Asia-PacificIPO

A Rising Star in Chinese Pharma Industry Marks Market Debut in Hong Kong

by Judy Ya-Hsuan Lin
Share To

By Judy Ya-Hsuan Lin

Simcere Pharmaceutical Group Limited is one of the top 100 pharmaceutical companies in China, and its major focuses are in cancer, central nervous system, and autoimmune diseases. Being the first Chinese pharma to be listed on the New York Stock Exchange in 2007, Simcere marked another milestone again in 2013 by completing its privatization by repurchasing shares.

On October 27th, Simcere was officially listed as HKEX:2096 on the Hong Kong Stock Exchange. According to the prospectus delivered by Simcere to the Hong Kong Stock Exchange, a total of 261 million shares priced at HK$13.70 per share were sold globally by that date, and the net proceeds are expected to reach approximately HK$3.57 billion. The funds raised on the Hong Kong Stock Exchange will be used for therapeutic development and commercialization. According to Simcere, 60% will be used in therapeutic research and development, and the remaining 40% will be utilized in commercialization.


Critical Milestones Marked

Simcere has consistently invested in innovative research and development for years, constantly marking milestones. The proportion of research and development costs has increased from 5.5% in 2017 to 23.6% in the first half of 2020. The proportion of revenue for the year 2018, 2019, and the first half of 2020 is 21.4%, 25.5%, 32.9%, and 40.4%, respectively.

This year, Simcere launched two blockbuster products. One is the first class of a new drug, which is edaravone, and dexcamphanol injection concentrated solution is the only stroke treatment drug approved for sale in the world within the past 5 years. The second is the rheumatoid arthritis biologic drug Enrexol, or abatacept injection, the world’s first T-cell co-stimulatory immunomodulator, which is developed in cooperation with Bristol-Myers Squibb. The sales of this drug reached $3.2 billion in 2019.


Product Portfolio & Pipeline in Innovative Transformation

Besides the tremendous expansion and medication approvals, Simcere’s R&D pipeline has 50 products under development at different stages. Among them, KN035 (envafolimab), a subcutaneously injectable PD-L1 inhibitor, is a product exclusively authorized in China.

Besides, Simcere has nearly 10 products under development that have obtained new drug clinical approvals or are undergoing clinical trials, including three CAR-T cell treatments for the popular target CD-19. They are self-developed small molecules, second-generation NTRK targeted drugs, and innovative small-molecule drugs for psoriasis. Among those newly approved drugs, the self-developed small molecule for tumor support therapy jointly developed by Simcere and G1 Therapeutics has been approved by the USFDA as a breakthrough therapy. It is expected to start a phase I clinical trial in China in 2021.

Related Article: Cambridge Startup’s Take Two at Public Debut is Off to a Slow Start



© All rights reserved. Collaborate with us:
Related Post
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
Kyverna’s Lupus Nephritis Cell Therapy Received FDA Clearance, Aiming for Phase 1 Trial in 2023
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top